Zenas BioPharma, Inc.’s ZBIO share price has surged by 11.76%, which has investors questioning if this is right time to sell.

Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k) regul ...

Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Zenas Biopharma in a research note issued to investors on Thursday, March 20th. Wedbush analyst M. Fan expects ...

Equities researchers at Zacks Research cut their Q1 2025 earnings estimates for Theravance Biopharma in a research note ...

Biotech firm Atai is the latest publicly traded company to announce a Bitcoin treasury strategy, starting with a $5 million ...

The Clinical Trials Arena team investigates the impact of government-led research funding cuts in clinical trials.

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines –NEW YORK, March 18, ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

PharmaCord is a high-growth pharma services company that serves as a commercialization partner for over 30 biopharmaceutical organizations with the goal of enhancing the patient experience.

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face ...

4. Israeli corporate Nasdaq Shareholders entitled to an exemption from Israeli withholding tax must provide the Tax Agent, by ...